回盛生物
(300871)
| 流通市值：43.50亿 | | | 总市值：43.50亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 864,930,090.25 | 458,217,021.87 | 1,681,248,059.49 | 1,259,534,029.86 |
| 营业总成本 | 702,717,089.76 | 363,647,395.52 | 1,414,179,951.34 | 1,066,684,555.95 |
| 其他经营收益 | | | | |
| 营业利润 | 233,575,939.05 | 87,332,499.05 | 290,474,559.25 | 216,564,082.86 |
| 利润总额 | 233,602,305.76 | 87,339,809.83 | 288,654,197.31 | 214,587,790.71 |
| 净利润 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 | 188,484,725.84 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | -2,310,824.87 |
| 综合收益总额 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 | 186,173,900.97 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,541,968,604.53 | 1,498,925,905.78 | 1,306,926,569.86 | 1,270,333,809.17 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,866,866,814.42 | 1,749,277,632.52 | 1,701,668,689.5 | 1,687,677,951.27 |
| 资产总计 | 3,408,835,418.95 | 3,248,203,538.3 | 3,008,595,259.36 | 2,958,011,760.44 |
| 流动负债: | | | | |
| 流动负债合计 | 753,654,037.68 | 777,872,921.52 | 740,331,111.74 | 745,165,592.68 |
| 非流动负债: | | | | |
| 非流动负债合计 | 329,489,800.43 | 202,366,754.84 | 81,834,982.61 | 94,772,523.92 |
| 负债合计 | 1,083,143,838.11 | 980,239,676.36 | 822,166,094.35 | 839,938,116.6 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,313,492,211.21 | 2,254,573,347.06 | 2,173,646,119.31 | 2,108,392,513.21 |
| 股东权益合计 | 2,325,691,580.84 | 2,267,963,861.94 | 2,186,429,165.01 | 2,118,073,643.84 |
| 负债和股东权益合计 | 3,408,835,418.95 | 3,248,203,538.3 | 3,008,595,259.36 | 2,958,011,760.44 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 765,026,843.49 | 370,373,613.04 | 1,402,634,527.29 | 991,584,938.53 |
| 经营活动现金流出小计 | 636,756,284.03 | 317,753,314.34 | 1,164,186,130.29 | 810,069,877.78 |
| 经营活动产生的现金流量净额 | 128,270,559.46 | 52,620,298.7 | 238,448,397 | 181,515,060.75 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 368,207,586.69 | 134,291,673.02 | 657,104,228.58 | 494,695,272.97 |
| 投资活动现金流出小计 | 652,378,782.44 | 263,366,542.94 | 711,944,904.46 | 639,792,156.12 |
| 投资活动产生的现金流量净额 | -284,171,195.75 | -129,074,869.92 | -54,840,675.88 | -145,096,883.15 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 451,089,796 | 212,630,102 | 258,824,132 | 227,358,689.85 |
| 筹资活动现金流出小计 | 243,681,698.74 | 95,527,049.97 | 419,062,890.42 | 295,411,357.08 |
| 筹资活动产生的现金流量净额 | 207,408,097.26 | 117,103,052.03 | -160,238,758.42 | -68,052,667.23 |
| 汇率变动对现金及现金等价物的影响 | -1,073,785.09 | -881,004.09 | -1,837,642.35 | -130,204.92 |
| 现金及现金等价物净增加额 | 50,433,675.88 | 39,767,476.72 | 21,531,320.35 | -31,764,694.55 |
| 期末现金及现金等价物余额 | 256,556,939.47 | 245,890,740.31 | 206,123,263.59 | 152,827,248.69 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 50,433,675.88 | - | 21,531,320.35 | - |
最新报告期：2026-08-18| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 西南证券 | 徐卿 | 1.73 | 2.07 | 2.59 | 2026-08-18 |